Scalper1 News
AbbVie’s hepatitis C regimen won FDA approval Friday, becoming the second entrant in what is already a huge market for interferon-free HCV treatments. The Viekira Pak will cost $83,319 for 12 weeks, in line with forecasts and undercutting Gilead Sciences’ (GILD) $94,500 for the same treatment length. The AbbVie (ABBV) regimen consists of three drugs: ombitasvir, paritaprevir (first developed by Enanta Pharmaceuticals (ENTA) and Scalper1 News
Scalper1 News